PYC — PYC Therapeutics Income Statement
0.000.00%
Last trade - 00:00- AU$699.91m
- AU$652.13m
- AU$22.86m
- 26
- 14
- 26
- 10
Annual income statement for PYC Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
C2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 2.6 | 3.18 | 16.1 | 15.9 | 22.9 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 9.64 | 21.8 | 30.3 | 39.2 | 60.4 |
| Operating Profit | -7.04 | -18.6 | -14.3 | -23.3 | -37.6 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -7.08 | -18.6 | -14.3 | -23.4 | -38.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -7.08 | -18.6 | -14.3 | -23.4 | -38.1 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -6.82 | -17.8 | -13.9 | -22.8 | -37.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -6.82 | -17.8 | -13.9 | -22.8 | -37.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.025 | -0.057 | -0.043 | -0.07 | -0.094 |